Drug
Epinastine clinical trials
- studies test it
- 11
- open now
- 0
- in phase 3
- 5
- first study started
- 1999
How studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2001 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 3 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 5
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Boehringer Ingelheim (5) · Merck Sharp & Dohme LLC (3) · Santen Pharmaceutical Co., Ltd. (2) · Hom, Milton M., OD, FAAO (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses epinastine is read from its arms, and is right about nine times in ten.
Testing it · 11
- Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic RhinitisCompletedPhase 2Merck Sharp & Dohme LLCNCT01382654Written as epinastine 0.1%
- A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic RhinitisCompletedPhase 2Merck Sharp & Dohme LLCNCT00407927Written as Epinastine Nasal Spray
- Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic ConjunctivitisCompletedPhase 4Merck Sharp & Dohme LLCNCT00534794Written as Elestat
- Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01363700Written as DE-114 ophthalmic solution
- Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02260050Written as WAL 801 CL dry syrup new formulation
- A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT01363713Written as DE-114 ophthalmic solution
- Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02182531Written as Epinastine
- WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic RhinitisCompletedPhase 3Boehringer IngelheimNCT02182544Written as WAL801CL dry syrup
- WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis PatientsCompletedPhase 3Boehringer IngelheimNCT02182557Written as WAL 801 CL Dry Syrup
- WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis PatientsCompletedPhase 3Boehringer IngelheimNCT02182570Written as WAL 801 CL dry syrup
- Comparison of CL Wear Between Two Allergy DropsWithdrawnPhase 4Hom, Milton M., OD, FAAONCT00489398Written as epinastine HCL and olopatadine HCL
Given in every arm · 1 — epinastine is usual care beside what is tested
As the comparator · 1 — what is tested is compared with epinastine
Codes
What other systems call epinastine · ClinicalTrials.gg INT003335
- MeSH (NLM) C053090epinastineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Q13WX941EFEPINASTINEConfirmed FDA, NLM, Wikidata
- RxNorm 39684Confirmed FDA, Wikidata
- Wikidata Q632405(RS)-epinastineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65515EpinastineOne source FDA
- DrugBank DB00751One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C053090 | epinastine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Q13WX941EF | EPINASTINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 39684 | — | Confirmed FDA, Wikidata |
| Wikidata | Q632405 | (RS)-epinastine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65515 | Epinastine | One source FDA |
| DrugBank | DB00751 | — | One source Wikidata |
Also registered as epinastine hydrochloride (UNII GFM415S5XL · RxNorm 236961).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.